Updated February 11, 2022
Notice ID: 07986
Related Notice: 61797
Award Number: 75D30120C07986
“Contract 75D30120C07986, “Virtual Network to Investigate COVID-19″ has six Objectives and associated Tasks associated with establishing a virtual network of healthcare and public health research systems with integrated medical, laboratory, and vaccination records for the purposes of assessing the epidemiology of mild to severe COVID-19 and evaluating the effectiveness of COVID-19 vaccines in preventing COVID-19 and associated medical burden among children and adults recommended to be vaccinated.”
“This contract modification includes changes in three tasks and the period of performance. CDC requires that the contractor expand the number of patients included in evaluations in order to:
- assess vaccine effectiveness (VE) among new populations, including children, who are now recommended to be vaccinated and new US regions such as the Southeast and Northeast regions (previously the populations were limited to early vaccine target groups and those in select US regions covered by the existing network sites);
- compare the preventive benefits of 3rd or booster vaccinations to the original 2-dose vaccination regimens (previously 3rd or booster vaccinations were not available); and
- assess the extent to which VE may decline due to reduced immunity with time since vaccination and/or changes in the virus variants circulating (previously Delta and Omicron variants as well as 3rd or booster doses were not considered in the study time period previously concluding in September 2022).”
“To accomplish these updated objectives, additional patient data extraction, validation, and management as well as fields of customized data gathering is required. Additionally, these new topics will require additional analysis and reporting beyond what was anticipated in the original contract (reporting will increase from bi-weekly to as frequent as weekly for datasets with new VE measures). The quantity of network sites will increase by up to four (4) additional sites in order to gain the full breadth of new populations. Finally, because the populations recommended for vaccination and their recommended vaccination regimen have changed recently, CDC requires that the contractor extend the study activities an additional study year to conclude 30 September 2023 instead of 30 September 2022…”
Updated December 3, 2021
“The Centers for Disease Control and Prevention intends to award a sole source cost reimbursable modification to Westat. Westat was awarded (4 May 2020) a contract (75D30120C07986; “Virtual Network COVID-19”) to establish a virtual network of health care and public health research systems with integrated medical, laboratory, and vaccination records for the purpose of assessing the epidemiology of mild to severe COVID-19 and evaluating the effectiveness of COVID-19 vaccines in preventing COVID-19 and associated medical burden among children and adults recommended to be vaccinated. Tasks include extracting and validating data elements, managing complex data sets, conducting descriptive and statistical analysis, reporting of results, and conducting focused investigations on specific research questions to address critical knowledge gaps relevant to public health policy decisions during the COVID-19 pandemic.”
“This effort was modified on 30 August 2020 (see Notice ID 07986) to expand information gathering to include vaccine records and to adapt protocols and procedures in order to assess effectiveness of licensed COVID-19 vaccines once they became available. CDC also required in this modification to expand the source population for the electronic cohorts from 2.5 million to 3.5 million members through expanded coverage within existing and new health care sites. CDC also required the period of performance to be extended to 30 September 2022 in order to conduct evaluations during the expected roll-out of COVID-19 vaccine products in the US and to evaluate the preventative benefits of vaccination over at least one year.”
“This effort was further modified on 17 March 2021 (see Notice ID 52217) for Westat to engage additional hospitals to contribute more hospitalization events in order to evaluate COVID-19 vaccine effectiveness (VE) in preventing lab-confirmed COVID-19 admissions and provide CDC with interim estimates of VE within 8 weeks of 2-dose vaccine coverage reaching >5% of the target population.
CDC requires an additional modification to expand the number of evaluated patients and special topics of investigation in order to: (1) assess VE among new populations, including children, who are now recommended to be vaccinated; (2) compare the preventative benefits of 3rd or booster vaccinations to the original 2-dose vaccination regimens; and (3) assess the extent to which VE may decline due to reduced immunity with time since vaccination and/or changes in the virus variants circulation. This modification requires an extension of the study period of performance through 30 September 2023.”
“Because Westat has completed all of the implementation tasks and study activities described above, they are the only contractor able to complete this work to add a larger source population and to add information relevant to vaccine evaluations which can be integrated with the existing and established data protocols. It is essential that this information be added to these existing cohorts rather than by initiating new studies in order for data to be comparable and collapsible; provide continuity in data sharing, analysis, and collaboration with study partners; and support rapid evidence-based policy decisions…”
Posted May 6, 2020
Westat has been awarded a 1-year $2M contract with the Centers for Disease Control and Prevention to establish a virtual network to investigate the trajectory of COVID-19 related severe outcomes.
Awardee Name: WESTAT, INC.
Contract Duration: 12 months
Total Contract Value: $1,743,949.00
Funding Agency: CENTERS FOR DISEASE CONTROL AND PREVENTION
Number of Bidders: 1
RFP ID: 75D30120R67973
Award ID: 75D30120C07986
